First-in-human study underway evaluating anti-CD36 monoclonal antibody designed to restore metabolic fitness in exhausted T cells, reduce immunosuppressive cells, and enhance antitumor immunity Pilatu ...
In the rapidly shifting landscape of multiple myeloma treatment, the roadmap for a patient diagnosed in 2026 looks vastly different than it did even a decade ago. In a recent interview with CURE, Dr.
Q4 2025 Earnings Call March 12, 2026 4:30 PM EDTCompany ParticipantsJennie WillsonJacqueline Shea - CEO, President ...
Alphamab Oncology (stock code: 9966.HK) announced that the Investigational New Drug (IND) application for JSKN021, an independently developed innovative dual payload bispecific antibody-drug conjugate ...
This quarter, MindWalk Holdings Corp. reported its third consecutive year-over-year revenue increase and advanced three ...
Thank you for joining us today for MindWalk Holdings Corp.'s Third Quarter Fiscal Year 2026 Earnings Call. MindWalk trades on the NASDAQ under the ticker HYFT. Today's call will be led by our Chief ...
Irish Examiner on MSN
Having a baby after PCOS and endometriosis: A complex fertility journey
Caitríona O’Donnell has endometriosis and polycystic ovary syndrome and knew she would need help to get pregnant. A new ...
MajesTEC-9 supports moving teclistamab earlier in myeloma treatment, with robust PFS and OS gains over standard care in the second-line setting, notes Roberto Mina, MD. AJMC: Given the 71% reduction ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results